New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.